![Dana Pizzuti](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dana Pizzuti
Geen lopende functies
Vermogen: 154 180 $ op 31-05-2026
Profiel
Dana Pizzuti worked at Gilead Sciences, Inc. as Vice President-Regulatory Affairs from 2007 to 2017.
Served as SVP-Regulatory Affairs & Quality at Rigel Pharmaceuticals, Inc. from 2017 to 2019.
Held the position of SVP-Regulatory Affairs & Quality at Theravance Biopharma, Inc. in 2019.
Worked as Vice President-Global Regulatory Affairs at Ascendis Pharma A in 2019 and later as Chief Medical Officer there from 2020 to 2022.
Held roles at Johnson & Johnson as Vice President-Global Regulatory Affairs and at Bristol-Myers Squibb AB as Vice President-Global Pharmacovigilance & Labeling.
Currently Chief Medical & Development Officer at Crinetics Pharmaceuticals, Inc. from 2022 to 2025.
Education includes undergraduate studies at Yale University and a doctorate from New York University School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-04-2026 | 4.337 ( 0% ) | 154 180 $ | 31-05-2026 |
Eerdere bekende functies van Dana Pizzuti
| Bedrijven | Functie | Einde |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 31-12-2025 |
| ASCENDIS PHARMA A/S | Hoofd Techniek/Wetenschap/O&O | 01-09-2022 |
| ASCENDIS PHARMA A/S | Algemeen Adviseur | 01-12-2019 |
| THERAVANCE BIOPHARMA, INC. | Corporate Officer/Principal | 01-07-2019 |
| RIGEL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-03-2019 |
Opleiding van Dana Pizzuti
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
59
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Johnson & Johnson
 Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Rigel Pharmaceuticals, Inc.
 Rigel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which discovers, develops and provides novel small-molecule drugs | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes therapies for metabolic, cardiovascular and ophthalmology | Health Technology |
Bristol-Myers Squibb AB
 Bristol-Myers Squibb AB Medical DistributorsDistribution Services Wholesales medical equipment and pharmacy | Distribution Services |
Theravance Biopharma, Inc.
 Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
New York University School of Medicine
 New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Crinetics Pharmaceuticals, Inc.
 Crinetics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets therapeutics for endocrine-related diseases | Health Technology |
